InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Nuvectis Pharma, Inc.

NVCT Clue Score43
United States Fiscal year ends December CIK 0001875558
$19.69 -6.77% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $19.69 +105.75% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 4 Feb 2022. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2021Operating income−12.9Net income−12.9EPS, diluted−3.02Fiscal year 2022Operating income−19.2Net income−19.1EPS, diluted−1.51Fiscal year 2023Operating income−22.9Net income−22.3EPS, diluted−1.43Fiscal year 2024Operating income−19.8Net income−19.0EPS, diluted−1.11Fiscal year 2025Operating income−27.6Net income−26.4EPS, diluted−1.32
FY2021FY2022FY2023FY2024FY2025
Operating income −12.9 −19.2 −22.9 −19.8 −27.6
Net income −12.9 −19.1 −22.3 −19.0 −26.4
Growth
EPS, diluted −3.02 −1.51 −1.43 −1.11 −1.32

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2021Operating cash flow−9.5Fiscal year 2022Operating cash flow−13.6Fiscal year 2023Operating cash flow−16.0Fiscal year 2024Operating cash flow−12.2Fiscal year 2025Operating cash flow−16.0
FY2021FY2022FY2023FY2024FY2025
Operating cash flow −9.5 −13.6 −16.0 −12.2 −16.0

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2021Cash5.7Shareholders’ equity−11.0Fiscal year 2022Cash20.0Shareholders’ equity14.2Fiscal year 2023Cash19.1Shareholders’ equity12.2Fiscal year 2024Cash18.5Shareholders’ equity9.7Fiscal year 2025Cash31.6Shareholders’ equity18.4
FY2021FY2022FY2023FY2024FY2025
Cash 5.7 20.0 19.1 18.5 31.6
Shareholders’ equity −11.0 14.2 12.2 9.7 18.4

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−9.5 −13.6 −16.0 −12.2 −16.0
Growth
Investment
n/a 0.0 0.0 0.0 n/a
Financing
15.2 27.8 15.1 11.7 29.1

Capital expenditure, dividends and buybacks are shown as money out, so negative.